

DENV1/DENV3 or 4

GTS1SP

TRBV	CDR3	TRBJ	Freq (%)
9	CASSAYQGTGELF	2-2	51.35
9	CASSLHGTSKLNQF	2-1	36.49
12-3/4	CASSFGGASYEQY	2-7	5.41
12-3/4	CASSFGNPEAF	1-1	5.41
23-1	CASSQGFDRTHTEAFF	1-1	1.35

GTS3SP

TRBV	CDR3	TRBJ	Freq (%)
11-2	CASSRGAGEQETQY	2-5	35.53
9	CASSVWGDPSEYEQY	2-7	28.95
9	CASSVADAGAISSGANVLT	2-6	13.16
11-2	CASSLGEQSSYNEQF	2-1	3.95
9	CASSLFGDPGTDQY	2-3	3.95
11-2	CASSLGGQGYEQY	2-7	3.95
7-8	CASSLYPSGRGDEQF	2-1	2.63
11-2	CASSFGQGDYGYT	1-2	2.63
11-2	CASSLGPDIYEQY	2-7	2.63
4-2	CASSQWVGSNTDQY	2-3	1.32
11-2	CASSFGVGTIEQY	2-7	1.32

TRBV	CDR3	TRBJ	Freq (%)
27	CATGTGGGYT	1-2	39.76
4-1	CASSPSWGRNQPH	1-5	12.05
9	CASSPPLAGFPYNEQF	2-1	10.84
4-1	CASSQGGYSNQPH	1-5	10.84
20-1	CSARDPGEYQETQY	2-5	9.64
15	CATSSPNSAGGYNEQF	2-1	4.82
19	CASSIEDSYNEQF	2-1	4.82
5-4	CASSFSGKGEQY	2-7	2.41
4-1	CASSPSGGRNQPH	1-5	1.20
7-8	CASSLGTGGYEQY	2-7	1.20
18	CASSPLSYNEQF	2-1	1.20
12-3/4	CASSLGTREAF	1-1	1.20

TRBV	CDR3	TRBJ	Freq (%)
11-2	CASSFLMGLAGNEQF	2-1	54.35
11-2	CASSLGGQYEQY	2-7	9.78
11-2	CASSLYTGSYNEQF	2-1	6.52
9	CASSVGGEQF	2-1	5.43
6-1	CASSDGIQY	2-4	5.43
7-9	CASSFVQFPYNEQF	2-1	4.35
12-3/4	CASNIGVNEQF	2-1	4.35
4-1	CASSPSWGRNQPH	1-5	3.26
11-2	CASSLDPGGYEQY	2-7	2.17
11-2	CASSLGPDIYEQY	2-7	2.17
11-2	CANSLFLMGLAGNEQF	2-1	1.09
9	CASNGGSVWGRETQY	2-5	1.09

Supplementary Figure 2 TRBV and TRBJ usage, CDR3 β amino acid sequence, and clonotype frequency are shown for CD3⁺CD8⁺CD14⁻CD19⁻ HLA-A*11:01-GTS1 or HLA-A*11:01-GTS3/4 tetramer⁺ populations isolated from patients with primary DENV1 infection or sequential DENV1/DENV3/4 infections. Recurrent clonotypes are highlighted in color. SP, single positive; GTS3, GTS3/4 (blue type).